NOVO-NORDISK A/S-SPONS ADR (NVO)
US6701002056 - ADR
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Could Structure Therapeutics Become the Next Novo Nordisk?
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
3 Best Stocks to Buy From the Fantastic 5
Although the best Fantastic 5 stocks offer much relevance and plenty of upside potential, they’re still underappreciated.
Where Will Madrigal Pharmaceuticals Be in 3 Years?
The coast is clear for it to grow, for now.
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks.
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
3 Stocks to Sell as Ozempic Surges in Popularity
GLP-1s are a weight-loss breakthrough, but these three stocks to sell have a lot to lose from their rapid rise in popularity.
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
They aren't the flashiest stocks, but they get the job done.
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's competition in the obesity drug market is heating up.
Weight Loss Drugs: Are They Really Magic?
Talking about weight and weight loss with Johann Hari, an Ozempic user and the author of "Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight-Loss Drugs."
3 Stocks to Buy as Ozempic Surges in Popularity
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
7 Trending Stocks With Momentum on Their Side
Trending stocks offer an opportunity to ride momentum higher and create quick returns for daring investors.
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly is serving a market that may reach $100 billion.
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Five mega companies may offer higher earnings and return potential with lower risk.
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device.
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity.
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy.
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk's stock may not look all that expensive when you're focusing on the long-term potential.
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run.
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines.
Why Quality Investors Should Delve into NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for Investment Opportunities.
Why Quality-Oriented Investors Should Consider NYSE:NVO.
Is Viking Therapeutics Stock a Buy on the Dip?
Short-term thinking is creating an intriguing opportunity for investors.
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
The market for treating chronic kidney disease is nearly within reach.